Breast Cancer

The Present and Future of Antibody-Drug Conjugates in Breast Cancer Therapy

Charu Aggarwal, MD, MPH; Paolo Tarantino, MD, PhD
Role of PIK3CA Testing in Newly Diagnosed Metastatic Breast Cancer Patients

Adrienne G. Waks, MD
Update on the Evolving Management of Metastatic HER2- Expressing Breast Cancer

Adrienne G. Waks, MD
Residual Risk in HER2+ Disease: Rethinking pCR, Recurrence, and CNS Protection

Jason A. Mouabbi, MD
The Future is Now: ctDNA in Breast Cancer

Jason A. Mouabbi, MD
Managing Acquired ESR1 Resistance Mutations in Advanced HR+ Breast Cancer

Adrienne G. Waks, MD
Early Stage HER2+ Breast Cancer

Jason A. Mouabbi, MD
“Seeing” the Estrogen Receptor: Unmasking the Power of FES-PET Imaging and its Clinical Utility

Jason A. Mouabbi, MD
When to Perform Genomic Testing for Patients with Metastatic Breast Cancer of Any Subtype

Adrienne G. Waks, MD
Unmasking Resistance: Rising ctDNA and ESR1 Mutation in Early-Stage HR+ Breast Cancer

Jason A. Mouabbi, MD
Evolving Management of HER2 Low and Ultralow Breast Cancer

Adrienne G. Waks, MD
ctDNA and MRD Assessment in Breast Cancer

Jason A. Mouabbi, MD